Insight 23
DHT blockers for hair loss: what works and who benefits?
Last reviewed
Published
Updated
A product labeled a DHT blocker may contain a prescription drug, a botanical extract or a mixture of ingredients. The label alone tells you little about how much it changes DHT or what improvement to expect.
The starting question is whether androgen activity is contributing to your hair loss. The answer helps establish which treatment fits, what else needs attention and how safety affects the choice.
What reducing DHT means
Dihydrotestosterone, or DHT, is made from testosterone. In susceptible scalp follicles, it contributes to the gradual production of finer hairs seen in androgenetic alopecia, or pattern hair loss. Finasteride and dutasteride inhibit the enzyme that makes DHT. They reduce its production by different amounts.1,2
Alopecia areata, infection and inflammation require treatment directed at their own causes. In a mixed case, androgen-directed treatment may address only the pattern hair loss component.
Other antiandrogens, such as spironolactone, reduce androgen action through different effects. DHT reduction and blocking an androgen receptor are distinct approaches.3
DHT has normal roles in the body, including male sexual development. Eliminating every effect of DHT is an inappropriate treatment goal. The aim is to improve the hair outcome with acceptable effects on the rest of your health.1,2
Hormone levels are part of the picture
Scalp thinning can occur with normal circulating androgen levels. Follicle sensitivity also matters. In women, thinning alongside unwanted facial or body hair, acne or irregular periods can prompt assessment for excess androgens.3
Polyendocrine metabolic ovarian syndrome, or PMOS, was formerly called PCOS. Its hormonal and metabolic features can influence care. Nutrition, physical activity, treatment of insulin resistance and management of menstrual or fertility concerns may belong in the wider plan. Scalp growth and unwanted hair can need additional treatment. Rapid changes or a deepening voice warrant prompt medical assessment for other causes of excess androgens.3,4
The best treatment choice depends on why your hair is changing and what else the treatment affects.
Compare the actual treatment
Finasteride is FDA-approved for male pattern hair loss. Dutasteride is used off label for hair loss in the US and Canada. Selected women also receive these drugs off label under a prescriber's care. Age, reproductive plans and the diagnosis shape that decision. Treatment can slow loss and support regrowth. Continued use is generally needed to maintain the benefit.1–3
Saw palmetto has clinical research behind it. In a two-year comparative study of 100 men, improvement was reported in 38% taking saw palmetto and 68% taking finasteride. Participants and researchers knew which treatment each person received. Its findings apply to the preparations tested; different extracts and combination products need their own evidence.5
Include sexual health and reproductive plans
Sexual side effects, breast symptoms and mood changes deserve discussion before treatment. Persistent sexual symptoms after stopping have been reported. Topical finasteride can enter the bloodstream, and applied product can transfer to another person.1,2,6 These drugs also lower PSA blood-test results, which the clinician needs to account for when interpreting prostate screening.1,2
Finasteride and dutasteride must be avoided during pregnancy because exposure can affect a male fetus. When pregnancy is possible, treatment requires effective contraception and a plan before conception. Someone who is pregnant should avoid crushed finasteride tablets and leaking dutasteride capsules. Breastfeeding safety has not been established for either drug; breastfeeding requires a drug-specific treatment plan.1–3
For a male partner, sperm production and fetal exposure are separate considerations. Dutasteride can alter semen measures. In a small infertility-clinic study, sperm counts improved after finasteride was stopped. Discuss conception plans and any fertility difficulty with the prescriber, including partner exposure precautions for the exact product.2,7
Choose around the whole case
Bring your product list and reproductive plans to the assessment. I use the scalp findings and health history to recommend whether androgen-directed treatment has a role, what other approaches belong alongside it and how the response should be reviewed with your prescriber.
References
- Organon. PROPECIA prescribing information. DailyMed. Accessed October 27, 2026. Return to text ↑
- Dutasteride prescribing information. DailyMed. Accessed October 27, 2026. Return to text ↑
- Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38:1655–1679. doi:10.1093/humrep/dead156. Return to text ↑
- Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407:2329–2339. doi:10.1016/S0140-6736(26)00717-8. Return to text ↑
- Rossi A, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25:1167–1173. doi:10.1177/039463201202500435. Return to text ↑
- FDA. Potential risks associated with compounded topical finasteride products. April 22, 2025. Return to text ↑
- Samplaski MK, et al. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100:1542–1546. doi:10.1016/j.fertnstert.2013.07.2000. Return to text ↑
